American Society of Hirudotherapy

A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition

Research article published in Journal of thrombosis and thrombolysis (2008)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryGenomics & ProteomicsDrug DevelopmentSalivary PharmacologyMo W et al. · Journal of thrombosis and thrombolysis, 2009

Abstract

BACKGROUND: Hirudin is an anti-coagulative product of the salivary glands of the medicinal leech Hirudo medicinalis. It is a powerful and specific thrombin inhibitor. Peptides containing the RGD motif competitively inhibit the binding of fibrinogen to GP IIb/IIIa on the platelets, thus inhibiting platelet aggregation. RESULTS: We have constructed a recombinant RGD-hirudin (r-RGD-hirudin) by fusing the tripeptide RGD sequence to the native hirudin (wt-hirudin). The r-RGD-hirudin was expressed at high levels in Pichia pastoris, and was purified to approximately 97% homogeneity. The specific anti-thrombin activity of purified r-RGD-hirudin is 12,000 ATU/mg, which is equivalent to wt-hirudin, but only r-RGD-hirudin can inhibit platelet aggregation. The biological effects of r-RGD-hirudin on Thrombin Time (TT), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Bleeding Time (BT), maximum platelet aggregation (PAGm) induced by ADP were studied in rabbit model and compared with that of wt-hirudin. The rabbits were infused r-RGD-hirudin had prolonged TT, PT, and aPTT which were similar to that of wt-hirudin; but only r-RGD-hirudin was capable of inhibiting PAGm. Histopathological analyses showed that r-RGD-hirudin was two to three times more effective than wt-hirudin in preventing thrombosis. CONCLUSIONS: r-RGD-hirudin can potentially be used as a novel anti-coagulant for the prevention of thrombosis after carotid artery anastomosis or in other thrombotic events.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAnticoagulantsBleeding TimeHirudinsMalePichiaPlasmidsPlatelet AggregationProtein EngineeringRabbitsRecombinant ProteinsThrombin

Summary

A recombinant RGD-hirudin fusion expressed in Pichia pastoris retained wild-type anti-thrombin activity (12,000 ATU/mg) and additionally inhibited ADP-induced platelet aggregation, being two to three times more effective than wild-type hirudin at preventing thrombosis in rabbits.

Why This Matters for Hirudotherapy

This study constructed a recombinant RGD-hirudin by fusing an RGD tripeptide to native hirudin from Hirudo medicinalis, expressed it in Pichia pastoris, and evaluated its dual anticoagulant and anti-platelet activities in rabbits. The r-RGD-hirudin retained equivalent anti-thrombin activity (12,000 ATU/mg) to wild-type hirudin while uniquely inhibiting ADP-induced platelet aggregation, and was two to three times more effective in preventing thrombosis histopathologically. The study engineers a bifunctional derivative of a leech-derived anticoagulant. This is a preclinical animal study; the molecule is a recombinant fusion construct rather than a natural leech secretion component, and no leeches or hirudotherapy were involved.

Citation

Reference (Vancouver style)

Mo W, Zhang YL, Chen HS, Wang LS, Song HY. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition. J Thromb Thrombolysis. 2009;28(2):230-237. doi:10.1007/s11239-008-0251-9. PMID: 18998199

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.